Pioneering the development of novel immunotherapies for patients with blood cancers and B-cell disorders.
The HaemaLogiX management team has deep expertise in immunotherapy development and the unique antigens that our treatments target. Our Scientific Advisory Board comprises internationally recognised experts in monoclonal antibodies and haematology.
We’re developing a suite of diverse immunotherapies including monoclonal antibodies, CAR-T cells and bispecific antibodies, with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis.
Our immunotherapies are designed to target and attack two unique antigens expressed on malignant cells – these antigens are not found on normal cells or tissues - making our treatments unlike others on the market.